Concept MedicalIn the journal "JACC: Cardiovascular Interventions》Publish an article about its drug-coated balloonMagicTouch SCBLarge-scale clinicalBed Research (EASTBOURNE). Research showsMagicTouch SCBTreatmentCoronary ArteryEfficacy of Pulse Disease Treatment Comparable to Drug-Eluting Stents。'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
EASTBOURNE is a prospective, multi-center, investigator-initiated clinical study that enrolled participants from real-world settings receivingMagicTouch SCBTreated patients. The primary endpoint was target lesion revascularization (TLR) at 12 months. Secondary endpoints included procedural success, myocardial infarction (MI), all-cause death, and major adverse cardiac events (MACE, a composite endpoint of death, myocardial infarction, and TLR). This study enrolled 2,123 patients (2,440 lesions) across 38 centers in Europe and Asia.Change). PatientThe average age was 66.6 ± 11.3 years, and 41.5% of the patients had diabetes. New lesions (small vessels) accounted for 56%, in-stent restenosis (ISR) accounted for 44%, and 7.7% of the patients underwent emergency stenting.- At 12 months post-surgery, the TLR rate for lesions was 5.9%, the MACE rate was 9.9%, and the rate of spontaneous myocardial infarction was 2.4%.
- The rates of cardiac death/all-cause mortality were 1.5% and 2.5%, respectively.
- The primary outcome (TLR) occurred at a higher rate in the ISR cohort (10.5% vs 2.0%). The main determinant of reaching the primary endpoint (TLR) in the final analysis was ISR.
EASTBOURNE is the largest DCB study in the coronary artery field, and its mid-term follow-up results indicate that this novel SCB demonstrates favorable safety and efficacy across a broad population of coronary artery disease, including patients with small vessel lesions and ISR.
MagicTouch SCBIt is a sirolimus-coated balloon.For Percutaneous Transluminal Coronary Angioplasty。Suitable for small coronary arteries with a vascular diameter of 1.50-2.75mm and lesion lengths of 6-36mm.。Of course,受限于球囊和载药涂层技术，MagicTouch SCBCurrently, the smallest applicable vessel size is 1.5mm, which covers mostCoronary Microvascular FunctionDisability (CMD)Not yet applicable, but addressing some unmet clinical needs is also a kind of clinical technological advancement. It is precisely this kind of progress.MagicTouch SCBAlso received the "Breakthrough Device" designation from the FDA.MagicTouch SCBCore Technology andConcept Medical PreviousMagicTouch Sirolimus-Coated BalloonThe technology is passed down from the same origin. Both adopt Nanolute technology.Phospholipids are drug carriers with two lipophilic tails and one hydrophilic head.MagicTouch SCBAdoptNanolute TechnologyEncapsulating sirolimus in phospholipids aims to enhance the lipophilicity and bioavailability of sirolimus. Additionally,MagicTouch SCBIt also boasts a unique coating technology, applying medication to the expanded balloon before folding it.MagicTouch SCB Drug Release
MagicTouch SCB Demonstration
Concept MedicalHeadquartered in Florida, USA, it is a medical device developer. The first to pioneerSirolimus Drug Delivery Platform Technology (Nanolute Technology),Nanolute TechnologyWith a proven commercial history in coronary applications for more than 60,000 patients globally. MagicTouch-SCB - Sirolimus-coated balloon developed using this nanotechnology for the treatment of CMD's small coronary lesions.
